期刊文献+

依普黄酮对蛋鸡产蛋性能及蛋品质的影响 被引量:6

Effects of ipriflavone supplementation on egg laying performance and egg quality of laying hens
在线阅读 下载PDF
导出
摘要 选140日龄健康罗曼蛋鸡1200羽,随机分为对照和3个试验组,每组设6个重复,每重复50羽。饲喂相同的基础饲粮,其中1组为对照组,其它3组为不同水平依普黄酮添加试验组。试验进行350d,并屠宰测定。结果显示,饲粮中添加20mgkg依普黄酮的日平均产蛋率增高了12.26%(P<0.01),料蛋比降低了9.92%(P<0.05)。蛋壳相对重和蛋壳厚度分别增加了13.51%(P<0.05)和6.92%(P<0.05)。且显著延长了产蛋率70%~80%和80%以上的高峰持续时间。另外,血清钙含量提高了19.48%(P<0.05),碱性磷酸酶活性和甲状旁腺激素水平也分别提高了17.05%(P<0.05)、26.33%(P<0.01)。上述结果可见,依普黄酮主要是通过提高与产蛋相关的各种生化指标和激素水平来达到改善蛋鸡的产蛋性能和蛋品质。
出处 《浙江农业科学》 2005年第4期325-327,共3页 Journal of Zhejiang Agricultural Sciences
  • 相关文献

参考文献12

  • 1何鹏,金一,马林,孟祥军,郑静,孙丽丽,吴秀霞.治疗骨质疏松新药——依普黄酮[J].中国新药杂志,1999,8(10):670-672. 被引量:7
  • 2聂晶,卢良华,孙军.预防和治疗骨质疏松症的有效药物依普黄酮[J].中国现代应用药学,2002,19(1):7-9. 被引量:22
  • 3杜旭虹,吴巧英.新型饲料添加剂——依普黄酮[J].浙江畜牧兽医,2003,28(1):15-15. 被引量:2
  • 4张宏昱,张石革.依普黄酮的研究进展与临床应用[J].中国药房,2003,14(12):758-759. 被引量:5
  • 5Hammone J M, Mondsschein J S, Samaras S E, et al. The ovarian insulin-like growth factors, a local amplifieation mechanism for steroidogenes and hormone action [J]. J Steroid Biochem MolBiol, 1991, 40: 411-416.
  • 6Chase J C, Kirby C J, Hammond A c, et al. Patterns of ovarian growth and development in cattle with a growth hormone receptordeficiency [J]. J Anitm Sci, 1998, 76: 212-219.
  • 7Buonomo F C, Baile C A. The neurophysiological regulation of growth hormone secretion [J]. Domestic Anim Endocrinol, 1990,7 (4): 435-450.
  • 8Arjmandi B H, Khan D A, Juma S S, et al. The ovarian hormone deficiency-induced hypercholesterolemia is reversed by soy protein and the synthetic isoflavone, ipriflavone [J]. Nutrition Research, 1997, 17 (5): 885-894.
  • 9Hiney J K, Srivastava V, Nyberg C L, et al. Insulin-like growth factor 1 of peripheral origin acts centrally to accelerate the initiation of female puberty [J]. Endocrinology, 1995, 12:223-245.
  • 10Bacon W L. Metabolism and ovarian follicular of the major yolk precursor in laying hens [J]. Poultry Science, 1985, 65:1184-1192.

二级参考文献29

  • 1裴春改,赵燕玲,刘忠厚.依普拉芬治疗骨质疏松的基础研究[J].中国骨质疏松杂志,1997,3(4):86-88. 被引量:15
  • 2Chinoin. Ipriflavone is an antiosteoporotic. Pharma project,Oct, 1999,10
  • 3Reginster JY, Bufalino L, Christiansen C, et al. Design for an Ipriflavone multicenter European fracture study. Calcif Tissue Int, 1997,61 (7):28
  • 4Adami S. Bufalino L, Cervetti R, et al. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporosis Int, 1997;7(2): 119
  • 5Choi YK, Han IK, Yoon HK. Ipriflavone for the treatment of osteoporosis. Osteoporos Int, 1997(7) Suppl. 3,S174
  • 6Agnusdei D,Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated Estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int. 1995(5) :462
  • 7Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone and Mineral, 1992(19)Suppl. S49
  • 8Shiota E. Evaluation of the drug therapy for osteoporosis by dual-energy X-ray absorptiometry. Fukuoka Igaku Zasshi.1998,89(6): 172
  • 9Gennari C, Adami S, Agnusdei D et al. Effects of chronic treatment with Iprifiavone in postmenopausal women with Iow bone mass. CalcifTissue Int. 1997,61 (7): 19.
  • 10Agnusdei D, Bufalino L. Efficacy of Iprifiavone in established Osteoporosis and long-term safety. Calcif Tissue Int, 1997,61(S uppl): S23

共引文献29

同被引文献70

引证文献6

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部